Thelansis

Primary Biliary Cholangitis (PBC) Emerging Therapy and TPP Insights Thelansis’s “Primary Biliary Cholangitis (PBC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Primary Biliary Cholangitis (PBC) Overview Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune cholestatic liver disease characterised by immune-mediated destruction of small intrahepatic bile ducts, driven by autoreactive T-cell targeting of mitochondrial antigens — predominantly the pyruvate dehydrogenase complex E2 subunit — in genetically susceptible individuals, with antimitochondrial antibodies (AMA) serving as the hallmark diagnostic biomarker present in over 90% of patients. Predominantly affecting middle-aged women, patients may prese...

Primary Biliary Cholangitis (PBC) Emerging Therapy and TPP Insights Thelansis’s “Primary Biliary Cholangitis (PBC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles ...